Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 2,646 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical Clear all
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Conversations You Want About Corona Virus Disease (COVID-19)

NCT05191420
View directory record Official record
Conditions
Covid19
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

Etanercept With Tacrolimus for Psoriasis

NCT00134394
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept plus tacrolimus
Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2008 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

Interstitial Cystitis

NCT00056251
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
H&P; ECG; Blood tests; voiding diary; Cystoscopy
Procedure
Lead sponsor
ICOS Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
24
States / cities
Anchorage, Alaska • Glendora, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)

NCT05269160
View directory record Official record
Conditions
Radiation Dermatitis, Breast Cancer
Interventions
Dermaprazole 1%, Dermaprazole 2%
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 4 Interventional Results available

Intraductal Meibomian Gland Probing Trial

NCT02256969
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
Blephamide, GenTeal PM Night-Time, Meibomian Gland Probing, Sham Meibomian Gland Probing
Drug · Procedure
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Testosterone Gel on Carbohydrate and Lipid Metabolism In Elderly Obese Men

NCT00365794
View directory record Official record
Conditions
Aging, Obesity, Insulin Resistance, Hypogonadism
Interventions
Topical testosterone gel 10 g/day
Drug
Lead sponsor
University of Southern California
Other
Eligibility
60 Years to 90 Years · Male only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Not applicable Interventional Results available

Lidocaine 5% Patch (Lidoderm) for the Prevention of Acute and Chest Pain Following Robotic Valve Surgery

NCT03120351
View directory record Official record
Conditions
Perioperative Chest Pain
Interventions
Lidoderm 5 % Topical Patch, Placebo patch
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC)

NCT00791102
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
ASP-1001 nasal spray, Placebo for ASP-1001
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Days to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer

NCT01653327
View directory record Official record
Conditions
Mucositis, Head and Neck Cancer
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2Phase 3 Interventional

Ozurdex for Macular Edema Post Membrane Peeling

NCT01273727
View directory record Official record
Conditions
Epiretinal Membrane, Cellophane Maculopathy, Macular Edema, Retinal Edema
Interventions
dexamethasone
Drug
Lead sponsor
Retina Specialists, PC
Other
Eligibility
21 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2015 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2 Interventional

Amelioration of Adverse Ocular Side Effects of Glaucoma Medications in Glaucoma Patients Using Topical GL101

NCT02656394
View directory record Official record
Conditions
Ocular Surface Disease
Interventions
GL101, Placebo
Drug
Lead sponsor
Glia, LLC
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm

NCT00942851
View directory record Official record
Conditions
Focal Dystonia
Interventions
Acetyl-Hexapeptide Topical Treatment, placebo
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

Topical DHEA Against Vaginal Atrophy

NCT01846442
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Placebo, DHEA (0.25%), DHEA (0.5%), DHEA (1.0%)
Drug
Lead sponsor
EndoCeutics Inc.
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cleveland, Ohio • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 2 Interventional Results available

A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts

NCT03981822
View directory record Official record
Conditions
Condylomata Acuminata, Papillomavirus Infections, Skin Diseases, Viral, Skin Diseases, Infectious, Skin Diseases, Sexually Transmitted Diseases, Viral, Sexually Transmitted Diseases, Warts
Interventions
VP-102 and applicator, Placebo
Combination Product
Lead sponsor
Verrica Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Plainfield, Indiana • Baton Rouge, Louisiana • Clarkston, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated Phase 4 Interventional Results available

Prospective Study on DEXTENZA® Safety And Efficacy Following Concomitant MIGS and Cataract Surgery

NCT04200651
View directory record Official record
Conditions
Glaucoma, Cataract
Interventions
Dexamethasone Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
The New York Eye Surgery Center
Other
Eligibility
21 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

A Multicenter, Double-blind, Randomized, Controlled, Roll-over Retreatment Study of the Safety and Pain Associated With Injections of PN40082, RV001 With Topical Anesthetic or RV001 for Lip Augmentation

NCT04029545
View directory record Official record
Conditions
Lip Augmentation
Interventions
PN40082
Device
Lead sponsor
Prollenium Medical Technologies Inc.
Industry
Eligibility
21 Years and older
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
5
States / cities
Encinitas, California • Miami, Florida • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 3 Interventional

Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder

NCT01506154
View directory record Official record
Conditions
Bursitis, Tendonitis, Shoulder Pain
Interventions
MRX-7EAT
Drug
Lead sponsor
MEDRx USA, Inc.
Industry
Eligibility
14 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis

NCT04605094
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Benralizumab, Placebo / Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 130 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Los Angeles, California • Newport Beach, California • Bridgeport, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Not applicable Interventional

"A Randomized, Controlled, Evaluator-blinded Pilot Study to Evaluate the Effect of Automated Text Message Reminders on Patient Compliance With Topical Medications and Its Efficacy on Skin Disease Control in Adolescents and Adults With Mild to Moderate Acne"

NCT01082523
View directory record Official record
Conditions
Acne, Patient Compliance
Interventions
Text message reminders
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
12 Years to 30 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2019 · Synced Oct 20, 2026, 6:20 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Clinical Efficacy of Two Topical Dry Eye Drops for Central Corneal Stain Clearing Over 90 Days

NCT04172961
View directory record Official record
Conditions
Dry Eye
Interventions
nanomicellular cyclosporine 0.09%, Lifitegrast
Drug
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced Oct 20, 2026, 6:20 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessing the Effects of a Topically Applied Cream to Clitoral Blood Flow

NCT01085981
View directory record Official record
Conditions
Female Sexual Dysfunction
Interventions
arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%, Topical study cream, GRAS cream
Drug
Lead sponsor
East Suburban Ob Gyn
Other
Eligibility
25 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 20, 2026, 6:20 PM EDT
Terminated Phase 1 Interventional

Study of QRH-882260 Heptapeptide Application in the Colon

NCT03148119
View directory record Official record
Conditions
Colon Cancer Prevention
Interventions
QRH-882260 Heptapeptide, Scanning Fiber Endoscope
Drug · Device
Lead sponsor
Danielle Kim Turgeon
Other
Eligibility
18 Years to 100 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 20, 2026, 6:20 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy and Safety of Adapalene/Benzoyl Peroxide Topical Gel in Subjects With Acne Vulgaris

NCT00422240
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene/Benzoyl Peroxide, Adapalene Gel, 0.1%, Benzoyl Peroxide Gel 2.5%, Gel Vehicle
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years and older
Enrollment
1,668 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 20, 2026, 6:20 PM EDT